Patients with known brain metastases should be excluded from this clinical trial
Patients with known brain metastases should be excluded from this clinical trial
Patients with known brain metastases should be excluded from this clinical trial
Patients with known brain metastases should be excluded from this clinical trial; previously treated brain metastases, neurologically stable, and no ongoing or anticipated need for steroid therapy are eligible
Patients with known brain metastases should be excluded from early clinical trials
Patients with clinically or radiologically unstable brain metastases are excluded from this clinical trial* Note: patients with stable brain metastases after treatment, for at least 3 months prior to enrolling on this trial, could participate in the study; patients should be off, or on a stable dose of steroids
Patients with known brain metastases should be excluded from this clinical trial
Patients with known brain metastases should be excluded from this clinical trial
Patients with known brain metastases should be excluded from this clinical trial
Participants with known brain metastases should be excluded from this clinical trial
Patients with known brain metastases should be excluded from this clinical trial
Patients with known brain metastases should be excluded from this clinical trial
Patients with known brain metastases should be excluded from this clinical trial
Patients with known brain metastases should be excluded from this clinical trial
Patients with known brain metastases are excluded
Patients with known brain metastases should be excluded from this clinical trial; a scan to confirm the absence of brain metastasis is not required
Patients with known brain metastases should be excluded from this clinical trial
Participants with known brain metastases should be excluded from this clinical trial
Patients with known brain metastases should be excluded from this clinical trial
Patients with known brain metastases should be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events
Patients with known brain metastases should be excluded from this clinical trial except as those described below
Patients with known active or history of brain metastases should be excluded from this clinical trial
Patients with known brain metastases should be excluded from this clinical trial
